查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922935

按药物类别、给药途径、治疗方法、分销管道和最终用户分類的直接抗病毒药物市场—2026-2032年全球预测

Direct Acting Antivirals Market by Drug Class, Route Of Administration, Treatment Regimen, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，直接作用抗病毒药物市场价值将达到 489.1 亿美元，到 2026 年将成长至 523.7 亿美元，复合年增长率为 8.13%，到 2032 年将达到 845.6 亿美元。

关键市场统计数据
基准年 2025 489.1亿美元
预计年份：2026年 523.7亿美元
预测年份 2032 845.6亿美元
复合年增长率 (%) 8.13%

对直接抗病毒药物生态系统进行策略性介绍，重点在于治疗突破、市场准入趋势、监管里程碑和相关人员的优先事项。

直接抗病毒药物（DAAs）重新定义了慢性C型肝炎的临床治疗方案，建立了标靶感染治癒性治疗的新典范。过去十年，临床疗效已从缓慢的病毒抑制转变为高且持续的病毒学反应率，从而实现了治疗方法更短、耐受性更好，并最大限度地减轻了长期疾病负担。随着临床疗效的提升，监管机构也改善了联合治疗的核准流程，促进了品牌药和学名药的上市，并提高了不同医疗体系中患者的治疗可及性。

治疗创新、分散式医疗服务、数位化转型和供应链重组如何重塑直接抗病毒药物（DAA）市场格局和相关人员的策略

直接抗病毒药物（DAA）领域正经历着变革性的转变，这主要得益于治疗创新、供应链重组以及医疗服务模式的演变。在临床上，泛基因型治疗方法和固定剂量组合药物的出现简化了治疗流程，并减少了对广泛基因分型检测的需求。更短的疗程和更高的耐受性扩大了患者群体，并将医疗服务下放至基层医疗和社区医疗机构。同时，真实世界数据和核准后安全性数据正在为治疗方法的迭代调整提供信息，并增强支付方对治疗结果的信心。

评估2025年美国关税如何改变了DAA供应链的采购、製造地和商业合约动态

自2025年起实施的美国关税政策，其累积影响已波及抗病毒疗法的采购惯例、供应商选择和製造地。某些药品成分关税的提高，导致活性药物成分（API）和复杂辅料的短期成本上升，迫使采购团队重新评估供应商合约和物流路线。为此，许多製造商加快了API和製剂生产的多元化进程，将生产分散到多个司法管辖区，以降低关税风险和运输瓶颈。这促使他们更加重视地域多角化和双重采购策略。

細項分析洞察：揭示药物类别、通路、给药途径和治疗方法结构对临床、商业性和营运的影响

细分市场分析按药物类别、分销管道、最终用户、给药途径和治疗方法，深入剖析了临床和商业性机会。依药物类别划分，市场细分为 Ns3/4A 蛋白酶抑制剂、Ns5A 抑制剂和 Ns5B聚合酵素抑制剂。 Ns3/4A 蛋白酶抑制剂又可细分为格卡瑞韦 (glecaprevir) 和伏西瑞韦 (voxilaprevir) 等药物；Ns5A 抑制剂则以联合治疗为主，例如雷迪帕韦-索非布韦 (ledipasvir-sofosbuvir) 和维帕Velpatasvir韦-索非亚布韦( Dasabuvir)及索非布韦 (sofosbuvir) 为代表。每类药物都有其独特的抗药性特征、药物交互作用考量和处方集定位，这些因素都会影响治疗方法的选择和临床路径的设计。

影响全球主要地区准入策略、生产决策和支付方参与的区域临床、监管和商业性趋势

区域趋势正在影响不同地区的药品取得、生产策略和支付方参与。在美洲，先进的支付方框架和集中化的生产能力推动了简化治疗方法的快速普及，而地方政府层面的药品获取差异则需要有针对性的定价和准入计划。在欧洲、中东和非洲地区，监管多样性和不同的采购机制既构成了挑战，也带来了机会。一些地区的集中采购与其他地区的分散市场结构形成鲜明对比，这需要量身定制的市场进入策略和公私合营。在亚太地区，高发地区、强大的学名药生产基地和先进的公共卫生项目并存，形成了一个竞争激烈的定价、以竞标为导向的竞标和创新应用并存的复杂环境。

药物研发策略、非专利竞争和策略联盟如何重塑产品系列优先事项、生产联盟和商业性管理

在直接授权仿製药（DAA）市场，企业层级的行为呈现出品牌药生产商的监管、非专利竞争和策略联盟三者并存的局面。品牌药生产商优先考虑智慧财产权管理、透过配方改善延长产品生命週期以及提供全面的实证医学证据，以维持其高端市场地位。同时，非专利生产商和授权非专利项目则利用本地化生产和简化的监管途径，在价格敏感的市场环境中提供价格更实惠的替代药物，并扩大患者的用药范围。策略联盟、授权协议和联合行销协议已成为协调全球监管要求与本地商业化能力的常用机制。

切实可行的策略性倡议，旨在加强供应链韧性，推动以患者为中心的药物研发，并使商业模式与支付方和医疗系统优先事项保持一致。

业界领导者可以采取切实可行的措施，在保障病人用药的同时，维持商业性的永续性。首先，透过拓展原料药（API）和成品药的生产，涵盖多个地区，并对二级供应商进行资格认证，从而增强供应链韧性，最大限度地减少中断。其次，优先开发固定剂量组合药物和有助于提高患者依从性的配方，以降低临床复杂性，并支持分散式医疗模式。第三，积极与支付方和医疗系统合作，透过真实世界数据、卫生经济学模型以及将临床获益与预算优先事项相结合的基本契约，展现产品的长期价值。

结合临床文献、监管审查、专家访谈和供应链分析等多方面透明研究方法，得出可操作的结论。

本研究采用多面向方法，整合多种资讯来源，确保研究结果严谨且具可操作性。调查方法包括：系统性回顾临床文献、分析监管核准和附加檔变更、检验产品处方集和分销管道结构，以及绘製製造地和供应链流程图。此外，还对临床专家、供应链经理和商业负责人进行了结构化访谈，以补充二手讯息，从而更好地理解实际应用中的药物使用模式、准入障碍和支付方奖励。

对直接授权协议 (DAA) 的机会和策略挑战进行简洁扼要的总结，重点在于准入、生产韧性和基于证据的商业化。

总之，直接抗病毒药物（DAA）是一个日益成熟的治疗领域，其临床疗效、简化的治疗方法和更高的耐受性相结合，使得在人群层面控制疾病成为可能。泛基因型疗法、固定剂量组合药物和不断扩大的分销管道的融合，有助于扩大治疗的可及性，但商业性成功需要精心协调生产策略、与支付方合作以及产品差异化特性。不断变化的贸易政策和区域准入趋势进一步加剧了策略环境的复杂性，因此，敏捷性和实证决策至关重要。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按药物类别分類的直接抗病毒药物市场

  • Ns3/4A蛋白酶抑制剂
    • 格卡瑞韦
    • 伏西拉普韦
  • Ns5A抑制剂
    • 雷迪帕韦 索非布韦
    • Velpatasvir/索非布韦
  • Ns5B聚合酵素抑制剂
    • Dasabuvir
    • 索非布韦

9. 按给药途径分類的直接抗病毒药物市场

  • 固定剂量组合药物
    • 每日一次给药
    • 每日两次给药
  • 单片装
    • 每日一次给药
    • 每日两次给药

10.治疗方法分類的直接抗病毒药物市场

  • 联合治疗
    • 双重疗法
      • Ns3 4A Ns5A
      • Ns5A Ns5B
    • 三联疗法
  • 单药治疗

第十一章 按分销管道分類的直接抗病毒药物市场

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 依最终用户分類的直接抗病毒药物市场

  • 医院
  • 零售药房
  • 专科诊所

13. 各地区直接作用抗病毒药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 直接作用抗病毒药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国直接抗病毒药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国直接作用抗病毒药物市场

第十七章：中国直接抗病毒药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson
  • Laurus Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Natco Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Pharco Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Strides Pharma Science Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-867BED9A9E69

The Direct Acting Antivirals Market was valued at USD 48.91 billion in 2025 and is projected to grow to USD 52.37 billion in 2026, with a CAGR of 8.13%, reaching USD 84.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 48.91 billion
Estimated Year [2026] USD 52.37 billion
Forecast Year [2032] USD 84.56 billion
CAGR (%) 8.13%

A strategic introduction to the direct acting antivirals ecosystem highlighting therapeutic breakthroughs, access dynamics, regulatory milestones and stakeholder priorities

Direct acting antivirals (DAAs) have redefined the clinical approach to chronic hepatitis C and established a paradigm for targeted, infection-curing therapeutics. Over the past decade clinical outcomes have transitioned from incremental viral suppression to high sustained virologic response rates, enabling short-course, well-tolerated regimens that minimize long-term disease burden. Alongside clinical efficacy, regulatory agencies have evolved approval pathways for combination regimens, fostering both originator and generic entries while increasing treatment accessibility in diverse health systems.

From a strategic perspective, stakeholders now operate at the intersection of clinical optimization and systems-level delivery. Payers and providers are refining formulary placement and access criteria to balance clinical benefit with budgetary constraints. Manufacturers focus on formulation innovation, real-world evidence generation, and lifecycle management to sustain differentiated value. These converging forces frame the current DAA ecosystem and set the priorities for innovation, commercialization, and policy engagement going forward.

How therapeutic innovation, delivery decentralization, digital enablement and supply chain realignment are reshaping the DAA landscape and stakeholder strategies

The DAA landscape is experiencing transformative shifts driven by therapeutic innovation, supply chain reconfiguration, and evolving care delivery models. Clinically, the emergence of pan-genotypic regimens and fixed-dose combinations has simplified treatment algorithms and reduced the need for extensive genotype testing. Shorter treatment durations and improved tolerability have widened the candidate pool for therapy, enabling decentralization of care into primary and community settings. At the same time, real-world evidence and post-approval safety data have informed iterative regimen adjustments and strengthened payer confidence in curative outcomes.

Commercially, manufacturers are responding with differentiated product strategies that emphasize adherence-friendly dosing and simplified logistics. The rise of online and specialty distribution channels complements traditional hospital and retail pharmacies, offering convenience and continuity for patients. Concurrently, digital health tools and telemedicine have accelerated remote monitoring and adherence support, enabling clinicians to manage therapy outside tertiary centers. These shifts collectively reposition DAAs from specialized hospital treatments to accessible, community-delivered cures that require integrated commercial and clinical strategies.

Assessment of how the 2025 United States tariff actions have shifted procurement, manufacturing footprints and commercial contracting dynamics across the DAA supply chain

The cumulative impact of the United States tariffs introduced in 2025 has reverberated across procurement practices, supplier sourcing, and manufacturing footprints for antiviral therapies. Increased tariffs on certain pharmaceutical inputs elevated the near-term cost base for active pharmaceutical ingredients and complex excipients, prompting procurement teams to reassess supplier contracts and logistics routes. In response, many manufacturers accelerated diversification of API and finished-dose manufacturing across multiple jurisdictions to mitigate tariff exposure and shipping bottlenecks, thereby increasing emphasis on regionalization of supply chains and dual-sourcing strategies.

Beyond direct cost implications, tariff-driven adjustments altered negotiation dynamics with distributors and payers. Contracting teams sought greater clarity on landed cost and total cost of therapy, while policymakers and regulators engaged with industry to preserve therapeutic access. For product teams and commercial leaders, the tariffs underscored the importance of supply chain transparency, localized manufacturing investments, and scenario planning to avoid disruption to patient access. Ultimately, the policy environment catalyzed a shift from single-source efficiency to resilient supply architectures that prioritize continuity of supply and price stability.

Segment-driven insights revealing clinical, commercial and operational implications across drug classes, channels, administration routes and regimen architectures

Segmentation analysis reveals nuanced clinical and commercial opportunities across drug class, distribution channel, end user, route of administration, and treatment regimen. Based on drug class, the market divides into Ns3/4A Protease Inhibitors, Ns5A Inhibitors, and Ns5B Polymerase Inhibitors, with the Ns3/4A Protease Inhibitors further distinguished by agents such as Glecaprevir and Voxilaprevir, the Ns5A Inhibitors explored through combinations like Ledipasvir Sofosbuvir and Velpatasvir Sofosbuvir, and the Ns5B Polymerase Inhibitors represented by Dasabuvir and Sofosbuvir. Each class carries distinct resistance profiles, drug-drug interaction considerations, and formulary positioning, which informs regimen selection and clinical pathway design.

Based on distribution channel, comparisons among hospital pharmacy, online pharmacy, and retail pharmacy reveal divergent fulfillment models and patient touchpoints that affect adherence support and post-prescription services. Based on end user, hospitals, retail pharmacies, and specialty clinics each present different engagement models for prescribers and patients, with hospitals often handling complex cases and specialty clinics enabling focused treatment pathways. Based on route of administration, fixed dose combinations and single agent tablets-and their once-daily versus twice-daily dosing variants-shape adherence dynamics and patient preference. Finally, based on treatment regimen, combination therapy and monotherapy split into dual and triple therapy permutations, with dual therapy combinations such as Ns3/4A plus Ns5A or Ns5A plus Ns5B and triple therapy across Ns3/4A, Ns5A and Ns5B offering options for treatment-experienced or resistant populations. These segmentation lenses together guide portfolio prioritization, clinical positioning, and channel strategy for maximizing patient reach and therapeutic impact.

Regional clinical, regulatory and commercial dynamics that determine access strategies, manufacturing decisions and payer engagement across key global territories

Regional dynamics shape access, manufacturing strategy, and payer engagement across distinct geographies. In the Americas, a combination of advanced payer frameworks and concentrated manufacturing capacity drives rapid uptake of simplified regimens, while disparities in access across subnational systems demand targeted pricing and access programs. In Europe, Middle East & Africa, regulatory heterogeneity and variable procurement mechanisms create both barriers and opportunities: centralized purchasing in some jurisdictions contrasts with fragmented markets in others, necessitating tailored market access strategies and public-private collaborations. In Asia-Pacific, high prevalence pockets coexist with a strong generics manufacturing base and progressive public health programs, which together create a complex environment of competitive pricing, volume-driven tendering, and innovation adoption.

These regional contours influence strategic decisions around manufacturing localization, licensing and partnership models, and patient support infrastructure. Regulatory pathways and reimbursement criteria differ by region, so lifecycle planning must account for varied registration timelines and health technology assessment requirements. Furthermore, regional digital health adoption and telemedicine penetration affect how providers engage patients, while localized patient assistance programs and community outreach remain essential to expand treatment uptake in underserved populations.

How originator strategies, generic competition and strategic partnerships are reshaping portfolio priorities, manufacturing alliances and commercial stewardship

Company-level behavior in the DAA landscape reflects a mix of originator stewardship, generic competition, and strategic alliances. Originator firms have prioritized intellectual property management, lifecycle extensions through formulation enhancements, and comprehensive evidence generation to preserve premium positioning. Concurrently, generic manufacturers and authorized generic programs have expanded access in price-sensitive settings, leveraging local manufacturing and streamlined regulatory pathways to deliver affordable alternatives. Strategic alliances, licensing agreements, and co-marketing arrangements have become common mechanisms to reconcile global regulatory requirements with local commercialization capabilities.

Commercial leaders must balance investment in brand-differentiating activities-such as adherence support, physician education, and real-world outcome tracking-with pragmatic pricing and access initiatives in markets where generics predominate. Manufacturing partnerships and contract development and manufacturing organizations play a pivotal role in scaling supply while maintaining quality standards. Portfolio managers should monitor competitor lifecycle activities, regulatory exclusivity timelines, and partnership opportunities to optimize launch sequencing and post-launch support for combination regimens and new formulations.

Practical strategic moves to enhance supply chain resilience, accelerate patient-centric formulations and align commercial models with payer and health system priorities

Industry leaders can take specific, actionable steps to protect patient access while preserving commercial viability. First, strengthen supply chain resilience by diversifying API and finished-dose manufacturing across multiple regions and by qualifying secondary suppliers to minimize disruption. Second, prioritize fixed-dose combination development and adherence-enhancing formulations that reduce clinical complexity and support decentralized care models. Third, engage proactively with payers and health systems to demonstrate long-term value through real-world evidence, health economic modeling, and outcome-based contracting that align clinical benefit with budgetary priorities.

Additionally, invest in digital adherence solutions and telehealth-enabled care pathways to support decentralized treatment and improve cure rates. Forge targeted partnerships with local manufacturers and procurement agencies to address pricing sensitivities in lower-resource settings while protecting intellectual property through structured licensing or voluntary agreements. Finally, embed scenario planning and policy monitoring into commercial planning to respond rapidly to trade policy changes, tariff shifts, or regulatory reforms that could affect access and pricing dynamics.

A transparent, multi-method research approach combining clinical literature, regulatory review, expert interviews and supply chain mapping to underpin actionable insights

This research synthesized diverse sources and applied a multi-method approach to ensure rigorous, actionable insights. The methodology combined systematic review of clinical literature, analysis of regulatory approvals and label changes, review of product formularies and distribution channel structures, and mapping of manufacturing footprints and supply chain flows. In addition, structured interviews with clinical experts, supply chain managers, and commercial leaders supplemented secondary data to contextualize real-world adoption patterns, access barriers, and payer incentives.

Data validation included cross-referencing regulatory documents, clinical trial registries, and published safety and effectiveness studies, as well as triangulation against industry press releases and procurement announcements. Where uncertainty existed, sensitivity analyses and scenario planning informed interpretive conclusions. Limitations of the approach include reliance on publicly available documentation for certain operational details and the lag inherent in published data compared with rapid policy or contract changes, which the methodology mitigated through targeted expert consultations and continuous update checks.

Concise synthesis of DAA opportunities and strategic imperatives emphasizing access, manufacturing resilience and evidence-driven commercialization

In summary, direct acting antivirals represent a maturing therapeutic area where clinical efficacy, simplified regimens, and improved tolerability converge to enable population-level disease control. The confluence of pan-genotypic therapies, fixed-dose combinations, and expanding distribution channels supports broader treatment access, yet commercial success requires careful alignment of manufacturing strategy, payer engagement, and differentiated product features. Trade policy changes and regional access dynamics further complicate the strategic environment, making agility and evidence-driven decision-making imperative.

For stakeholders across industry, healthcare delivery, and policy, the priority is to translate clinical opportunity into sustainable access. That requires coordinated efforts to shore up supply chains, invest in formulations and adherence supports that fit decentralized care, and forge commercial agreements that reflect long-term clinical and economic value. When executed coherently, these steps will ensure the full therapeutic promise of DAAs is realized across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Direct Acting Antivirals Market, by Drug Class

  • 8.1. Ns3/4A Protease Inhibitors
    • 8.1.1. Glecaprevir
    • 8.1.2. Voxilaprevir
  • 8.2. Ns5A Inhibitors
    • 8.2.1. Ledipasvir Sofosbuvir
    • 8.2.2. Velpatasvir Sofosbuvir
  • 8.3. Ns5B Polymerase Inhibitors
    • 8.3.1. Dasabuvir
    • 8.3.2. Sofosbuvir

9. Direct Acting Antivirals Market, by Route Of Administration

  • 9.1. Fixed Dose Combinations
    • 9.1.1. Once Daily Dosing
    • 9.1.2. Twice Daily Dosing
  • 9.2. Single Agent Tablets
    • 9.2.1. Once Daily Dosing
    • 9.2.2. Twice Daily Dosing

10. Direct Acting Antivirals Market, by Treatment Regimen

  • 10.1. Combination Therapy
    • 10.1.1. Dual Therapy
      • 10.1.1.1. Ns3 4A Ns5A
      • 10.1.1.2. Ns5A Ns5B
    • 10.1.2. Triple Therapy
  • 10.2. Monotherapy

11. Direct Acting Antivirals Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Direct Acting Antivirals Market, by End User

  • 12.1. Hospitals
  • 12.2. Retail Pharmacies
  • 12.3. Specialty Clinics

13. Direct Acting Antivirals Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Direct Acting Antivirals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Direct Acting Antivirals Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Direct Acting Antivirals Market

17. China Direct Acting Antivirals Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Aurobindo Pharma Limited
  • 18.9. Bayer AG
  • 18.10. Biogen Inc.
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. Cipla Limited
  • 18.14. Dr. Reddy's Laboratories Ltd.
  • 18.15. Eli Lilly and Company
  • 18.16. Gilead Sciences, Inc.
  • 18.17. GlaxoSmithKline plc
  • 18.18. Hetero Labs Limited
  • 18.19. Johnson & Johnson
  • 18.20. Laurus Labs Limited
  • 18.21. Lupin Limited
  • 18.22. Merck & Co., Inc.
  • 18.23. Natco Pharma Limited
  • 18.24. Novartis AG
  • 18.25. Pfizer Inc.
  • 18.26. Pharco Pharmaceuticals
  • 18.27. Regeneron Pharmaceuticals, Inc.
  • 18.28. Roche Holding AG
  • 18.29. Sanofi S.A.
  • 18.30. Strides Pharma Science Limited
  • 18.31. Takeda Pharmaceutical Company Limited
  • 18.32. Teva Pharmaceutical Industries Ltd.
  • 18.33. Vertex Pharmaceuticals Incorporated
  • 18.34. Viatris Inc.
  • 18.35. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIRECT ACTING ANTIVIRALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 223. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 260. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 262. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 271. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 273. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 275. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)